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Abstract
Background: Recent evidence suggests that the activation of a non-specific lipid scramblase during
apoptosis induces the flipping of sphingomyelin from the cell surface to the cytoplasmic leaftet of
the plasma membrane. Inner leaflet sphingomyelin is then cleaved to ceramide by a neutral
sphingomyelinase. The production of this non-membrane forming lipid induces blebbing of the
plasma membrane to aid rapid engulfment by professional phagocytes. However contrary evidence
suggests that cells which are deficient in acid sphingomyelinase are defective in apoptosis signalling.
This data has been interpreted as support for the activation of acid sphingomyelinase as an early
signal in apoptosis.
Hypothesis: An alternative explanation is put forward whereby the accumulation of intracellular
sphingomyelin in sphingomyelinase deficient cells leads to the formation of intracellular rafts which
lead to the sequestration of important signalling molecules that are normally present on the cell
surface where they perform their function.
Testing the hypothesis: It is expected that the subcellular distribution of important signalling
molecules is altered in acid sphingomyelinase deficient cells, leading to their sequestration in late
endosomes / lysosomes. Other sphingolipid storage diseases such as Niemann-Pick type C which
have normal acid sphingomyelinase activity would also be expected to show the same phenotype.
Implications of the hypothesis: If true the hypothesis would provide a mechanism for the
pathology of the sphingolipid storage diseases at the cellular level and also have implications for the
role of ceramide in apoptosis.
Background
Recently reported data shed further light on the interre-
lationships between caspase activation, the scrambling
of membrane phospholipid asymmetry and the produc-
tion of ceramide which can occur during apoptosis sig-
nalling. Firstly, since signalling by the caspase cascade
can occur very rapidly elucidation of whether ceramide
production or caspase activation comes first is of great
importance. A large body of evidence now suggests that
inhibition of inducer caspases such as FLICE also inhibit
ceramide formation [1–3]. These observations suggest
that ceramide generation is downstream of the early sig-
nalling events in apoptosis. Moreover, late generation of
ceramide indicates that ceramide formation may be a
consequence of the execution of apoptosis rather than a
signal. During the execution of apoptosis the activation
of a non-specific phospholipid membrane scramblase
leads to the general disruption of phospholipid asymme-
try, the externalisation of phosphatidylserine and mem-
brane blebbing. Membrane blebbing and
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phosphatidyserine exposure signal a physiological end-
point since they lead to engulfment by professional
phagocytes and rapid clearance from the tissue.
As early as the 1980's it was suggested that ceramide pro-
duction and membrane blebbing are linked [4]. Allan
and co-workers reported that treatment of chicken
erythrocytes with Ca2+ ionophore A21387 led to a loss of
membrane phospholipid asymmetry and membrane
blebbing presumably through the activation of a non-
specific phospholipid scramblase. Scrambling of mem-
brane asymmetry was associated with increases in cera-
mide by the action of an intracellular sphingomyelinase.
More recently, van Blitterswijk and co-workers have
found that activation of a non-specific phospholipid
scramblase during Fas-mediated apoptosis is responsi-
ble for the generation of ceramide [5]. They show that
this ceramide is derived from cell surface sphingomyelin
and is cleaved due to flipping of external sphingomyelin
towards the inner leaflet of the plasma membrane by an
intracellular sphingomyelinase. Simultaneously, inner
leaflet phosphatidylserine is flipped to the cell surface.
Thus ceramide generation may be a consequence of
intercellular signalling for phagocytosis of apoptotic
cells. Breakdown of sphingomyelin and the production of
ceramide may be very important for the changes in cell
morphology that occur during apoptosis. In contrast to
sphingomyelin, ceramide is a hydrophobic lipid without
a polar headgroup that does not form membrane bilayers
in aqueous enviroments. Ceramide formed from the hy-
drolysis of sphingomyelin is expected to accumulate in
the membrane interior and lead to membrane blebbing.
Simultaneously, removal of cell surface sphingomyelin
also has a destabilising effect since sphingolipids form
complexes (rafts) with cholesterol. This is due to hydro-
gen bonding between the hydroxyl group of cholesterol
and the hydroxyl group of the sphingosine backbone as
well as hydrophobic van der waals interactions with the
saturated acyl chains that tend to be enriched in sphin-
golipids. These changes would be expected to be impor-
tant in facilitating the changes in membrane curvature
that occur during blebbing allowing rapid phagocytosis
and by-passing the potentially damaging inflammation
that occurs during necrotic cell death. However, recent
evidence that acid sphingomyelinase deficient cells have
defects in apoptotic signalling pathways have been inter-
preted as strong evidence for the role of ceramide in sig-
nalling. This is despite disparate results with acid
sphingomyelinase deficient cells [6]. Indeed it has been
observed that splenocytes derived from a NPD mouse in
which the acid sphingomyelinase gene has been knocked
out can show enhanced apoptosis at advanced stages of
the disease [7]. Still it has been claimed that these para-
doxical results are due to abnormally large levels of
sphingomyelin accumulation in older mice and that
young mice that do not store large amounts of sphingo-
myelin are defective in apoptosis [8]. These results have
been interpreted to support the activation of a sphingo-
myelinase in a signalling cascade that is an important in-
itial event in apoptosis ie before the activation of inducer
caspases [9–11]. In order to clarify some of these issues
the following hypothesis is proposed:
Presentation of the hypothesis
An alternative explanation for the observed defects in ap-
optosis signalling in acid sphingmyelinase deficient cells
It is hypothesised that changes in apoptosis signalling in
these cells are due to indirect effects of decreased sphin-
gomyelin breakdown rather than the inhibition of cera-
mide formation. Recent evidence suggests that
sphingolipid-enriched rafts form sorting platforms for
specific proteins and lipids in the endocytic pathway per-
haps especially in the endocytic sorting of specific mem-
brane components to the Golgi apparatus [12,13].
Lysosomal accumulation of sphingomyelin is expected to
disrupt endoctyic trafficking of important raft-associat-
ed cell surface signalling molecules. Sphingomyelin is
usually rapidly broken down in the late endosomes and
lysosomes. In acid sphingomyelinase deficient cells
sphingomyelin can be kinetically trapped in this or-
ganelle even in young mice which do not store large
amounts of sphingomyelin. Through its association with
cholesterol this leads to the formation of rafts in the late
endosomes and disruption of the normal trafficking of
raft associated proteins and lipids.
Testing the hypothesis
Defects in apoptosis signalling would be expected to oc-
cur in other sphingolipid storage disorders, such as gly-
cosphingolipid storage disorders and Niemann-Pick type
C which are not defective in sphingomyelinase. Cells
storing large amounts of sphingolipid should show
changes in the subcellular location of signalling mole-
cules, especially those which are associated with rafts
[14].
Implications of the hypothesis
The accumulation of sphingomyelin in the lysosome of
these cells may have diverse consequences for the cell's
biology including the increased localisation of raft-asso-
ciated proteins which normally cycle through the early
endocytic pathway and Golgi apparatus with the lyso-
some [12,13]. Such an effect may be expected to lead to
reduced surface expression of raft-associated receptors
and their effectors. Inhibition of acid sphingomyelinase
induces a lipid traffic jam and may lead to the sequestra-
tion and consequent inactivation and breakdown of raft-
associated proteins in the lysosome. Such events may
contribute indirectly to decreased apoptotic signalling.BMC Cell Biology 2001, 2:24 http://www.biomedcentral.com/1471-2121/2/24
If true, the evidence suggests a role for ceramide in the
blebbing of apoptotic cells in the execution phase of ap-
optosis to aid their rapid clearance by professional
phagocytes. This role is in contrast to the structurally re-
lated lipid, diacylglycerol, which serves as a second mes-
senger in many agonist stimulated events.
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